Although the results, such as the failure to assemble a stable ternary complex, may not be as satisfactory as expected, there may be an encouraging breakthrough similar to BRD4-targeting PROTAC, which can effectively degrade BRD4 [39, 40], so the topic is worth exploring, and we are looking forward to the gratifying research results in the field of PROTACs against DOT1L in MLL-rearranged leukemias in the near future. This evidence concerns the gene KMT2A and leukemia.